JP2024508824A - ミトコンドリアグリセロール－３－リン酸アシルトランスフェラーゼ（ｇｐａｍ）阻害剤による肝疾患の治療 - Google Patents

ミトコンドリアグリセロール－３－リン酸アシルトランスフェラーゼ（ｇｐａｍ）阻害剤による肝疾患の治療 Download PDF

Info

Publication number
JP2024508824A
JP2024508824A JP2023551999A JP2023551999A JP2024508824A JP 2024508824 A JP2024508824 A JP 2024508824A JP 2023551999 A JP2023551999 A JP 2023551999A JP 2023551999 A JP2023551999 A JP 2023551999A JP 2024508824 A JP2024508824 A JP 2024508824A
Authority
JP
Japan
Prior art keywords
seq
complement
guanine
gpam
position corresponding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023551999A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508824A5 (https=
Inventor
アンドレア ロッタ、ルカ
フェルヴァイ、ニーク
オダシュレイン、コルム
マルキーニ、ジョナサン
バラス、アリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2024508824A publication Critical patent/JP2024508824A/ja
Publication of JP2024508824A5 publication Critical patent/JP2024508824A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023551999A 2021-02-27 2022-02-25 ミトコンドリアグリセロール－３－リン酸アシルトランスフェラーゼ（ｇｐａｍ）阻害剤による肝疾患の治療 Pending JP2024508824A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163154693P 2021-02-27 2021-02-27
US63/154,693 2021-02-27
PCT/US2022/017899 WO2022182985A1 (en) 2021-02-27 2022-02-25 Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (gpam) inhibitors

Publications (2)

Publication Number Publication Date
JP2024508824A true JP2024508824A (ja) 2024-02-28
JP2024508824A5 JP2024508824A5 (https=) 2025-01-27

Family

ID=80786652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023551999A Pending JP2024508824A (ja) 2021-02-27 2022-02-25 ミトコンドリアグリセロール－３－リン酸アシルトランスフェラーゼ（ｇｐａｍ）阻害剤による肝疾患の治療

Country Status (10)

Country Link
US (2) US12215322B2 (https=)
EP (1) EP4297772A1 (https=)
JP (1) JP2024508824A (https=)
KR (1) KR20230151996A (https=)
CN (1) CN116867510A (https=)
AU (1) AU2022227748A1 (https=)
CA (1) CA3210481A1 (https=)
IL (1) IL304543A (https=)
MX (1) MX2023009986A (https=)
WO (1) WO2022182985A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526482A (ja) * 2008-07-03 2011-10-13 サンタリス ファーマ アー／エス ミトコンドリアグリセロール−３−リン酸アシルトランスフェラーゼ１（ｍｔｇｐａｔ１）の発現を阻害するためのｒｎａアンタゴニスト化合物
WO2019165232A1 (en) * 2018-02-23 2019-08-29 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of phospholipid synthesis and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9149445B2 (en) 2009-07-27 2015-10-06 The Trustees Of Princeton University Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections
WO2021252649A2 (en) * 2020-06-09 2021-12-16 Alnylam Pharmaceuticals, Inc. Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526482A (ja) * 2008-07-03 2011-10-13 サンタリス ファーマ アー／エス ミトコンドリアグリセロール−３−リン酸アシルトランスフェラーゼ１（ｍｔｇｐａｔ１）の発現を阻害するためのｒｎａアンタゴニスト化合物
WO2019165232A1 (en) * 2018-02-23 2019-08-29 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of phospholipid synthesis and methods of use

Also Published As

Publication number Publication date
EP4297772A1 (en) 2024-01-03
US20220307032A1 (en) 2022-09-29
US12215322B2 (en) 2025-02-04
US20250197866A1 (en) 2025-06-19
MX2023009986A (es) 2023-09-06
CN116867510A (zh) 2023-10-10
AU2022227748A1 (en) 2023-08-10
CA3210481A1 (en) 2022-09-01
IL304543A (en) 2023-09-01
AU2022227748A9 (en) 2024-05-09
KR20230151996A (ko) 2023-11-02
WO2022182985A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
JP2024502282A (ja) 細胞死誘導ｄｆｆａ様エフェクターｂ（ｃｉｄｅｂ）阻害剤での肝疾患の治療
US20220411870A1 (en) Treatment Of Obesity With G-Protein Coupled Receptor 75 (GPR75) Inhibitors
US20260078378A1 (en) Treatment Of Sepsis With PCSK9 And LDLR Modulators
US20250188473A1 (en) Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) Inhibitors
US12215322B2 (en) Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors
US20250129366A1 (en) Treatment Of Liver Disease Or Metabolic Disorder With Folliculin Interacting Protein 1 (FNIP1) Inhibitors And/Or Folliculin (FLCN) Inhibitors
JP2024509157A (ja) リングフィンガータンパク質２１３（ｒｎｆ２１３）阻害剤による肝疾患の治療
US20230160012A1 (en) Treatment of Liver Diseases With CAMP Responsive Element Binding Protein 3 Like 3 (CREB3L3) Inhibitors
US20240247267A1 (en) Treatment Of Stroke With 1,4-Alpha-Glucan-Branching Enzyme (GBE1) Inhibitors
US20230037524A1 (en) Methods Of Treating Skin Cancer With Carboxypeptidase Vitellogenic Like (CPVL) Inhibitors
CN117597132A (zh) 用环指蛋白213(rnf213)抑制剂治疗肝病
KR20260060325A (ko) 폴리큘린 상호작용 단백질 1 (fnip1) 억제제 및/또는 폴리큘린 (flcn) 억제제를 이용한 간 질환 또는 대사 장애의 치료
KR20260062947A (ko) 폴리큘린 상호작용 단백질 1 (fnip1) 억제제 및/또는 폴리큘린 (flcn) 억제제를 이용한 근육 장애의 치료

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260217